Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Lung Cancer

Free Subscription 27.11.2023 1 Am J Clin Oncol 1 Am J Pathol 1 Ann Oncol 2 Ann Surg Oncol 1 Ann Thorac Surg 1 Arch Bronconeumol 2 BMC Cancer 1 Br J Cancer 2 Cancer 1 Cancer Lett 1 Chest 7 Clin Lung Cancer 1 Clin Nucl Med 2 Eur J Cancer 2 Eur J Cardiothorac Surg 6 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 2 J Clin Oncol 1 J Nucl Med 3 J Thorac Cardiovasc Surg 13 J Thorac Oncol 3 JAMA Oncol 3 Lung Cancer 1 Oncogene 1 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. YANG L, Lu X, Luo J, Huang D, et al
   Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
   Am J Clin Oncol. 2023 Nov 20. doi: 10.1097/COC.0000000000001066.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. LAMI K, Ota N, Yamaoka S, Bychkov A, et al
   Standardized Classification of Lung Adenocarcinoma Subtypes and Improvement of Grading Assessment Through Deep Learning.
   Am J Pathol. 2023;193:2066-2079.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. TRAN HT, Heeke S, Sujit S, Vokes N, et al
   Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer.
   Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. MACHADO PFA, Pimenta S, Garcia AL, Nogueira T, et al
   ASO Visual Abstract: Effect of Preoperative Home-Based Exercise Training on Quality of Life After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
   Ann Surg Oncol. 2023 Nov 17. doi: 10.1245/s10434-023-14602.
   PubMed        
   
   
5. MACHADO PFA, Oliveiros B, Martins RA, Cruz J, et al
   ASO Author Reflections: Impact of a Preoperative Home-Based Exercise Program on Quality of Life After Lung Cancer Resection.
   Ann Surg Oncol. 2023 Nov 19. doi: 10.1245/s10434-023-14620.
   PubMed        
   
   

   
   Ann Thorac Surg

6. COLLINS ML, Mack SJ, Whitehorn GL, Till BM, et al
   Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States.
   Ann Thorac Surg. 2023 Nov 21:S0003-4975(23)01165.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

7. ESTEBAN V, Javaloyes J, Martinez-Lopez S, Sancho-Chust JN, et al
   Alveolar Macrophage Expression Differs According to Lung Cancer Subtype.
   Arch Bronconeumol. 2023 Nov 9:S0300-2896(23)00363.
   PubMed        
   
   

   
   BMC Cancer

8. LI S, Wang W, Yu H, Zhang S, et al
   Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
   BMC Cancer. 2023;23:1115.
   PubMed         Abstract available
   
   
9. JIN S, Liu T, Wang W, Li T, et al
   Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis.
   BMC Cancer. 2023;23:1125.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al
    Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
    Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491.
    PubMed         Abstract available
    
    

    
    Cancer

11. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.
    PubMed        
    
    
12. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.
    PubMed        
    
    

    
    Cancer Lett

13. KONG R, Wei W, Man Q, Chen L, et al
    Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
    Cancer Lett. 2023;578:216442.
    PubMed         Abstract available
    
    

    
    Chest

14. ZHANG Y, Liang H, Cheng J, Choudhry AA, et al
    Associations between Sex-Specific Reproductive factors and Risk of New-Onset Lung Cancer Among Women.
    Chest. 2023 Nov 15:S0012-3692(23)05709-4. doi: 10.1016/j.chest.2023.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. GROSS AJ, Sheikh S, Kharouta M, Chaung K, et al
    The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series.
    Clin Lung Cancer. 2023;24:696-705.
    PubMed         Abstract available
    
    
16. NAKAMICHI S, Kubota K, Matsuyama K, Misumi T, et al
    A Phase ? Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
    Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00186.
    PubMed         Abstract available
    
    
17. PIRZADEH M, Lagina M, Wood C, Valley T, et al
    Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.
    Clin Lung Cancer. 2023 Oct 31:S1525-7304(23)00226.
    PubMed         Abstract available
    
    
18. QIN A, Wells L, Malhotra B, Gadgeel S, et al
    A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Oct 26:S1525-7304(23)00224.
    PubMed         Abstract available
    
    
19. VISONA G, Spiller LM, Hahn S, Hattingen E, et al
    Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers.
    Clin Lung Cancer. 2023;24:e311-e322.
    PubMed         Abstract available
    
    
20. FARIA N, Lacerda C, Lopes J, Viana C, et al
    PET-CT SUV(max) and Endobronchial Ultrasound Features for Prediction of Malignancy: A Prospective Study.
    Clin Lung Cancer. 2023;24:753-760.
    PubMed         Abstract available
    
    
21. LI S, Chen M, Wang Y, Li X, et al
    An Effective Malignancy Prediction Model for Incidentally Detected Pulmonary Subsolid Nodules Based on Current and Prior CT Scans.
    Clin Lung Cancer. 2023;24:e301-e310.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

22. TAO Z, Qiu Y, Huang W, Wang A, et al
    Small Cell Carcinoma of the Ureter With Early Recurrence and Multiple Metastases Shown on 18F-FDG PET/CT.
    Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004828.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

23. RATAIN MJ, Strohbehn GW
    Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
    Eur J Cancer. 2023;194:113349.
    PubMed         Abstract available
    
    
24. WENG PC, Huang YL, Cheng CY
    Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
    Eur J Cancer. 2023;196:113432.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

25. WANG MM, Li JQ, Dou SH, Li HJ, et al
    Lack of Incremental Value of Three-Dimensional Measurement in Assessing Invasiveness for Lung Cancer.
    Eur J Cardiothorac Surg. 2023 Nov 17:ezad373. doi: 10.1093.
    PubMed         Abstract available
    
    
26. ZHANG M, Liu X, Ge M
    Prevalence and anatomical characteristics of medial-basal segment in right lung.
    Eur J Cardiothorac Surg. 2023;64:ezad342.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. SAFAVI AH, Palma DA, Giuliani ME
    Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?
    Int J Radiat Oncol Biol Phys. 2023;117:1232-1235.
    PubMed        
    
    
28. SIVA S, Staehler M
    The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
    Int J Radiat Oncol Biol Phys. 2023;117:1047.
    PubMed        
    
    
29. RAMESH S, Cifci A, Javeri S, Minne R, et al
    MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 16:S0360-3016(23)08139.
    PubMed         Abstract available
    
    
30. AHN J, Yeghiaian-Alvandi R, Hegi-Johnson F, Browne LH, et al
    SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
    Int J Radiat Oncol Biol Phys. 2023;117:1213-1221.
    PubMed         Abstract available
    
    
31. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2023;117:1222-1231.
    PubMed         Abstract available
    
    
32. LEE SH, Geng H, Arnold J, Caruana R, et al
    Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;117:1270-1286.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

33. ZHANG J, Song L, Li G, Liang A, et al
    Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
    J Cancer Res Clin Oncol. 2023;149:17199-17213.
    PubMed         Abstract available
    
    
34. XU M, Hao Y, Shi Z, Song Z, et al
    Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
    Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
    J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
    PubMed         Abstract available
    
    
36. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed         Abstract available
    
    

    
    J Nucl Med

37. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

38. DYAS AR, Bronsert MR, Stuart CM, Thomas MB, et al
    Analyzing the Impact of the COVID-19 Pandemic on Initial Oncologic Presentation and Treatment of Non-Small Cell Lung Cancer in the United States.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01098.
    PubMed         Abstract available
    
    
39. SULLIVAN KA, Farrokhyar F, Patel YS, Liberman M, et al
    Preoperative Mediastinal Staging in Early-Stage Lung Cancer: Targeted Nodal Sampling is Not Inferior to Systematic Nodal Sampling.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01096.
    PubMed         Abstract available
    
    
40. 
    Discussion to: Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)00979.
    PubMed        
    
    

    
    J Thorac Oncol

41. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    PubMed         Abstract available
    
    
42. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    PubMed         Abstract available
    
    
43. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    PubMed         Abstract available
    
    
44. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.
    PubMed        
    
    
45. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.
    PubMed        
    
    
46. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.
    PubMed        
    
    
47. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.
    PubMed        
    
    
48. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    PubMed         Abstract available
    
    
49. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    PubMed         Abstract available
    
    
50. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    PubMed         Abstract available
    
    
51. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    PubMed         Abstract available
    
    
52. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    PubMed         Abstract available
    
    
53. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

54. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.
    PubMed        
    
    
55. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    PubMed         Abstract available
    
    
56. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    PubMed         Abstract available
    
    

    
    Lung Cancer

57. LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al
    Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report.
    Lung Cancer. 2023;186:107424.
    PubMed         Abstract available
    
    
58. SAKATA Y, Saito G, Sakata S, Oya Y, et al
    Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
    Lung Cancer. 2023;186:107426.
    PubMed         Abstract available
    
    
59. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
    Lung Cancer. 2023;186:107422.
    PubMed         Abstract available
    
    

    
    Oncogene

60. SUN X, Dai Y, He J, Li H, et al
    D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.
    Oncogene. 2023;42:3503-3513.
    PubMed         Abstract available
    
    

    
    PLoS One

61. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed         Abstract available
    
    

    
    Thorax

62. LI Y, Chen W, Xie F, Huang R, et al
    Novel electromagnetic navigation bronchoscopy system for the diagnosis of peripheral pulmonary nodules: a prospective, multicentre study.
    Thorax. 2023;78:1197-1205.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.